Judith Brownell

Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.

Thierry Brue, Isabelle Pellegrini, Ginette Gunz et al. · The Journal of Clinical Endocrinology & Metabolism · 1992 · 70 citations

Prl Hypersecretion, Molecular Pharmacology, Oncology +12

Inhibitory action of a met-enkephalin on ACTH release in man.

E. del Pozo, Jorge Martı́n-Pérez, Andreas M. Stadelmann et al. · Journal of Clinical Investigation · 1980 · 64 citations · Full text

Mg Fk 33824, Molecular Pharmacology, Adrenal Gland +15

The Efficacy and Tolerability of CV 205–502 (a Nonergot Dopaminergic Drug) in Macroprolactinoma Patients and in Prolactinoma Patients Intolerant to Bromocriptine

A. J. van der Lely, Judith Brownell, Steven W. J. Lamberts · The Journal of Clinical Endocrinology & Metabolism · 1991 · 55 citations

Prl-secreting Tumors, Cv 205–502, Macroprolactinoma Patients +14

A DOUBLE‐BLIND STUDY COMPARING A NEW NON‐ERGOT, LONG‐ACTING DOPAMINE AGONIST, CV 205‐502, WITH BROMOCRIPTINE IN WOMEN WITH HYPERPROLACTINAEMIA

Roy Homburg, Christine R. West, Judith Brownell et al. · Clinical Endocrinology · 1990 · 53 citations

CV 205–502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia

P. F. M. van der Heijden, W. de Wit, Judith Brownell et al. · European Journal of Obstetrics & Gynecology and Reproductive Biology · 1991 · 43 citations · Full text

Molecular Pharmacology, Cv 205–502, New Dopamine Agonist +6